Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.

Zhang, Shaohua; Li, Lei; Wang, Tao; Bian, Li; Hu, Haixu; Xu, Chunhong; Liu, Bing; Liu, Yi; Cristofanilli, Massimo; Jiang, Zefei

Zhang, Shaohua; Li, Lei; Wang, Tao; Bian, Li; Hu, Haixu; Xu, Chunhong; Liu, Bing; Liu, Yi; Cristofanilli, Massimo; Jiang, Zefei.

Afiliação

Zhang S; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.
Li L; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.
Wang T; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.
Bian L; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.
Hu H; Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA, 19107, USA.
Xu C; Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA, 19107, USA.
Liu B; Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA, 19107, USA.
Liu Y; Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA, 19107, USA. liuyi790114@163.com.
Cristofanilli M; Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China. massimo.cristofanilli@jefferson.edu.
Jiang Z; Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China. jiangzefei@medmail.com.cn.

BMC Cancer ; 16: 526, 2016 07 25.

Article em En | MEDLINE | ID: mdl-27456503

Assuntos

Antineoplásicos/uso terapêutico; Biomarcadores Tumorais/metabolismo; Neoplasias da Mama/metabolismo; Células Neoplásicas Circulantes/metabolismo; Receptor ErbB-2/metabolismo; Adulto; Idoso; Neoplasias da Mama/tratamento farmacológico; Neoplasias da Mama/mortalidade; Neoplasias da Mama/patologia; Intervalo Livre de Doença; Feminino; Humanos; Estimativa de Kaplan-Meier; Pessoa de Meia-Idade; Modelos de Riscos Proporcionais; Resultado do Tratamento

Palavras-chave

Anti-HER2 therapy; Circulating Tumor Cells (CTCs); Human Epidermal Growth Factor Receptor 2 (HER2); Metastatic Breast Cancer (MBC); Real-time HER2 status

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / Células Neoplásicas Circulantes / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google